NeuroNews’ top 10 most popular stories of December 2025

Several highlights from the Society of Vascular and Interventional Neurology (SVIN) annual meeting (19–22 November 2025, Orlando, USA) feature on NeuroNews’ final top 10 of the year, while two major regulatory approvals in chronic subdural haematoma (SDH) management and new data on a range of novel neurovascular devices were also popular with our readers throughout December.

1. Initial neurovascular cases find 7Fr-compatible radial guide catheter safe and effective

The first tranche of cases utilising a novel radial guide catheter have suggested safety and effectiveness with the device, potentially expanding the applicability of transradial access approaches across a number of neurovascular procedure types. That is according to data presented recently at the 2025 SVIN annual meeting.

2. Onyx gains US indication for MMA embolisation in chronic subdural haematoma patients

Medtronic announced this week that its Onyx liquid embolic system is now indicated for embolisation of the middle meningeal artery (MMA)—as a surgical adjunct—to treat patients with symptomatic subacute or chronic SDH in the USA.

3. Procedural choices matter but vascular penetration has minimal impact on MMAe outcomes, new analyses find

Sub-analyses of two randomised controlled trials (RCTs) have found that, while the extent of vascular penetration appears to have a minimal bearing on outcomes, both procedural sequencing and surgical technique selection may significantly influence the therapeutic benefits of MMA embolisation (MMAe) in chronic SDH patients.

4. Fully automated intracranial pressure diagnostic secures 2025 SVINnovation prize

A novel solution intended to tackle one of the “biggest blind spots” in modern medicine—intracranial pressure (ICP) assessment—recently won the fourth annual SVINnovation competition, walking away from the 2025 SVIN annual meeting with US$150,000 in prize money.

5. GRASSROOT trial findings support expansion of “value-priced thrombectomy devices” in resource-poor settings

The GRASSROOT trial evaluating the Supernova stent retriever (Gravity Medical Technology) has found “excellent” safety and efficacy outcomes in the treatment of large vessel occlusion (LVO) strokes, potentially supporting the wider adoption and reimbursement of “value-priced thrombectomy devices” in low- and middle-income countries (LMICs).

6. J&J MedTech receives US FDA approval for Trufill n‑BCA liquid embolic system in symptomatic cSDH treatment

Johnson & Johnson (J&J) MedTech announced that the US Food and Drug Administration (FDA) has approved an expanded indication for the Trufill n‑BCA liquid embolic system covering embolisation of the MMA as an adjunct to surgery in the treatment of symptomatic subacute and chronic SDH.

7. In-vivo thrombectomy data indicate improved clot ingestion and FPE rates with Von Vascular’s Algo smart pump

Von Vascular has announced what it describes as “compelling” new in-vivo data on its Algo smart pump featuring adaptive pulsatile aspiration (APA). These data were presented during a late-breaking session at the 2025 SVIN annual meeting by Robert Starke (Miami, USA).

8. Sentante conducts first remote stroke thrombectomy procedures in living subjects

Medical robotics company Sentante has conducted its first study involving live subjects, with surgeons using its unique haptic endovascular platform on animal models from three different remote locations.

9. Artiria secures CE mark for Smartguide 014 deflectable guidewire with articulating tip

Artiria Medical has announced that its Smartguide 014 deflectable guidewire—a next-generation guidewire specifically developed for neurovascular interventions—has received CE-mark certification under the European Medical Device Regulation (MDR).

10. iVascular announces first enrolment in 4-NiVO study assessing distal thrombectomy with new iNstroke 4Fr catheter

iVascular has initiated the 4-NiVO clinical study to evaluate the efficacy and safety of its iNstroke 4Fr thromboaspiration catheter in acute ischaemic stroke patients with distal/medium-vessel occlusions (DMVOs) who are treated within 24 hours from symptom onset.


LEAVE A REPLY

Please enter your comment!
Please enter your name here